首页|探讨多西环素在幽门螺杆菌根除治疗中的作用

探讨多西环素在幽门螺杆菌根除治疗中的作用

扫码查看
目的 探讨多西环素在根除幽门螺杆菌治疗中的作用.方法 将120例幽门螺杆菌阳性患者随机分为3组,均采用四联疗法,3组均应用雷贝拉唑肠溶胶囊20mg、枸橼酸铋钾胶囊胶囊0.6g、阿莫西林胶囊1g,每日2次口服治疗;治疗组(A组)40例,加用盐酸多西环素片1g,每日2次口服治疗;对照治疗组(B组)40例,加用克拉霉素分散片0.5g,每日2次口服治疗;对照治疗组(C组)40例,加用左氧氟沙星片0.5g,每日1次口服治疗;各组治疗时间均为2周,比较各组幽门螺杆菌根除率及不良反应发生率.结果 治疗组与对照治疗组患者幽门螺杆菌根除率差异无统计学意义(P>0.05);3组患者的不良发应发生率比较,差异无统计学意义(P>0.05).结论 在根除幽门螺杆菌治疗中,多西环素与其他四联方案中抗生素发挥等效作用,且更易被患者接受,可作为新的根除幽门螺杆菌治疗方案使用.
The Investigation of the Effect of Doxycycline on Eradication of Helicobacter Pylori
Objective To investigate the role of doxycycline in Helicobacter Pylori eradication therapy.Methods A total of 120 Helicobacter Pylori positive patients were enrolled and randomly divided into 3 study groups,all of which received quadruple therapy.Rabeprazole enteric-coated capsule 20mg,bismuth potassium citrate capsule 0.6g,amoxicillin capsule 1g,and oral treatment twice a day were given to all three groups.The treatment group(Group A),with 40 cases,also received doxycycline hydrochloride tablet 1g,twice a day with oral treatment,while the control group(Group B),with 40 cases,also received clarithromycin disperse tablet 0.5g,twice a day with oral treatment and the other control group(Group C),with 40 cases,also received levofloxacin tablet 0.5g,once a day with oral treatment;The treatment duration of each group was 2 weeks.The eradication rate of Helicobacter Pylori and the incidence of adverse reactions were compared among all three groups.Results There was no significant difference in Helicobacter Pylori eradication rate between the treatment group and the control group(P>0.05).There was no significant difference in the incidence of adverse reactions among all three groups(P>0.05).Conclusion For Helicobacter Pylori eradication therapy,doxycycline can play an equivalent role with other antibiotics in quadruple regimens,and is more acceptable to patients.This approach can be used as a novel Helicobacter Pylori eradication treatment.

Helicobacter PyloriDoxycyclineTreatment outcome

刘刚、王韶华

展开 >

北京中西医结合医院脾胃病科,北京 100039

幽门螺杆菌 多西环素 治疗结果

2024

标记免疫分析与临床
中国同辐股份有限公司

标记免疫分析与临床

CSTPCD
影响因子:0.978
ISSN:1006-1703
年,卷(期):2024.31(8)